Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice.
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Japanese macaque encephalomyelitis: a spontaneous multiple sclerosis-like disease in a nonhuman primate.
Episode 46 with Dr. Hans Lassmann on biomarkers in NMO and MS
ACTRIMS-ECTRIMS 2014 -- Day 2, morning
Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis.
American Society for Neurochemistry 47th Annual Meeting
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.
Direct immunomodulatory influence of IFN-β on human astrocytoma cells.
Episode 62 with Dr. Ellen Mowry on vitamin D and caloric restriction for MS
Episode 44 with Dr. Monika Bradl on an animal model for neuromyelitis optica (NMO)
MS Research Roundup: July 17, 2014
ACTRIMS-ECTRIMS 2014 -- Day 3, afternoon
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)
Gender-specific expression of beta1 integrin of VLA-4 in myelin basic protein-primed T cells: implications for gender bias in multiple sclerosis.
An ADIOL-ERβ-CtBP transrepression pathway negatively regulates microglia-mediated inflammation.
Episode 55 with Dr. Michael Levy on the status of regenerative stem cell therapies for multiple sclerosis
FP187 – Oral Immunomodulatory Dimethyl Fumarate (DMF)
Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a.
Mycophenolate mofetil for relapsing-remitting multiple sclerosis.
ACTRIMS-ECTRIMS 2014 -- Day 2, afternoon
The pathology of acute disseminated encephalomyelitis produced experimentally in the rhesus monkey and its resemblance to human demyelinating disease.
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study.
Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex.
No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.

Pages